Answers are grounded in this paper and cite their sources.
Neuroendocrine tumors were thrust to the forefront of the on-cologyworld last year with themuch-heralded approval of two drugs, everolimus and sunitinib, for the treatment of advanced pancreatic neuroendocrine tumors.1,2 The large, prospective randomized trials leading to these approvals were a clear break from the recent past, when clinical practice was based, in large part, on small institutional series andanecdotal experience.Lesswellpublicizedhavebeenparallel advances in thedevelopmentofmethods to increaseunderstandingof the clinical behavior of this diverse group ofmalignancies. TheAmer-ican Joint Committee on Cancer (AJCC) and similar organizations recently adopted formal pathologic staging and histologic classifica-tion schemes for neuroendocrine tumors. In the article that accompa-nies this editorial, Strosberg et al3 report on a large series ofmore than 600 small bowel carcinoid tumors and evaluate how well these new systems work.
No takes yet. Share an insight, caveat, or question.
Matthew H. Kulke (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: